You are here
VASCULAR VISION PHARMACEUTICAL CO
UEI: CZQSE8JMCEN1
# of Employees: 3
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management
Amount: $2,027,049.00Summary: Sickle cell disease (SCD) primarily afflicts African-Americans in the US, exacerbating an existing health disparity. Approximately 1 in 13 African-American babies is born with the sickle cell ...
SBIRPhase II2022Department of Health and Human Services National Institutes of Health -
Multi-Modal Mechanisms of Novel Sulfated Non Anticoagulant Heparin inSickle Cell Disease Management
Amount: $215,058.00AbstractThe pathogenesis of Sickle cell diseaseSCDcomprises a complex interplay of factors associated with vascular endothelial activationintense inflammationand increased sickle cell adhesionMicrovas ...
STTRPhase I2019Department of Health and Human Services National Institutes of Health -
Topic 374: Topical Delivery of Nanoformulated Bioactive Chemopreventive Agent in Skin Cancer
Amount: $288,945.00We plan to evaluate the chemopreventive management of solar ultraviolet (UV) mediated DNA damage by two different Nanoformulation of epigallicatechin-3-gallate (EGCG). The formulations to be assessed ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Enabling high dose regional chemotherapy while minimizing systemic toxicity
Amount: $159,306.00DESCRIPTION (provided by applicant): Enabling high dose regional chemotherapy with minimal systemic toxicity Abstract: The primary objective of this proposed study is to develop a filtration system th ...
STTRPhase I2010Department of Health and Human Services National Institutes of Health -
Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer
Amount: $128,350.00DESCRIPTION (provided by applicant): The development of resistance to chemotherapy represents an adaptive biological response by tumor cells that leads to treatment failure and patient relapse. There ...
STTRPhase I2007Department of Health and Human Services National Institutes of Health -
Enhancing tumor uptake of chemotherapeutics by novel heparin-derived compounds
Amount: $100,000.00DESCRIPTION (provided by applicant): Many cancer patients reportedly have a hypercoagulable state with recurrent thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on the co ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Tissue Factor/Vlla modulation in Ocular angiogenesis
Amount: $100,000.00DESCRIPTION (provided by applicant): Diabetic retinopathy is the most common cause of new-onset vision loss in young people in the USA and other industrialized countries, and retinal neovascularizatio ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
kininiogen in Ocular angiogenesis-mediated disorders
Amount: $100,000.00Retinal and choroidal angiogenesis are major causes of vision loss, and the pathogenesis of this angiogenesis process is still unclear. However, several key steps of the angiogenic cascade have been e ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health
